Overview

Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification

Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
The following trial hypothesis will be proved: In patients with atrial fibrillation and/ or pulmonary embolism standard anticoagulant treatment with coumadin/phenprocoumon is associated with accelerated coronary or valvular calcification as assessed by cardiac computed tomography compared to the new anticoagulant therapy with rivaroxaban.
Phase:
Phase 4
Details
Lead Sponsor:
RWTH Aachen University
Collaborator:
Bayer
Treatments:
Phenprocoumon
Rivaroxaban
Vitamin K